Video

Giving Patients Autonomy During Difficult Conversations

Author(s):

Joshua Richter, M.D.

A new patient-reported outcomes tool is helping to shift the way end-of-life and depression-related conversations are occurring between patients with multiple myeloma and their health care teams.

A new patient-reported outcomes tool is helping to shift the way end-of-life and depression-related conversations are occurring between patients with multiple myeloma and their health care teams, according to Joshua Richter, M.D., a hematologist/oncologist specializing in multiple myeloma at the John Theurer Cancer Center.

The tool guided patients to rank their depression and anhedonia (inability to feel pleasure), and provided meaningful insight on patients who are ready to go to palliative care or end their treatment. End-of-life discussions are never easy, but this helped to give the patient more autonomy in the conversation.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Robotic and minimally invasive kidney cancer surgery may reduce pain, shorten recovery time and preserve kidney function, according to Dr. Armine Smith.
Image of Doctor.
Building long-term trust with providers can help patients with MPNs feel supported, encourage them to speak up and navigate care with confidence.
The field of radiation oncology has advanced in brain cancer treatment with precise therapeutic approaches including proton and carbon therapy.
Image of Dr. Doug
Image of doctor.
Image of Dr. Kelly
Image of Dr. Boffa.
Immune Therapy Expands Melanoma Treatment to More Patients
Bladder preservation for bladder cancer requires balancing clinical factors and patient health with a personalized treatment plan.
Related Content
Ronald Chin received a diagnosis of multiple myeloma in January 2017 and has been in remission since October 2023. Catch up on all of Ronald's blogs here!
May 13th 2025

I Found Strength After Surviving Multiple Myeloma and Through Recovery

Ronald Chin
I share how I survived multiple myeloma, painful spine fractures and years of recovery to reclaim my independence and vitality.
Top Headlines on CAR-T Cell Therapy
December 4th 2023

Top Headlines on CAR-T Cell Therapy

Alex Biese Brielle Benyon
From FDA concerns to a potential new drug, CAR-T cell therapies were dominating oncology headlines last week.
Dr. Suresh S. Ramalingam explains that patients with stage 3 lung cancer who undergo chemotherapy and radiation may develop radiation pneumonitis.
May 7th 2025

Managing Lung Inflammation After Chemoradiation and Tagrisso

Dr. Suresh S. Ramalingam
Dr. Suresh S. Ramalingam explains that patients with stage 3 lung cancer who undergo chemotherapy and radiation may develop radiation pneumonitis.
Health Care Worker Discusses Cancer Diagnosis and Vaccine Experience While on the Frontlines of the COVID-19 Pandemic
January 13th 2022

Health Care Worker Discusses Cancer Diagnosis and Vaccine Experience While on the Frontlines of the COVID-19 Pandemic

Jamie Cesanek
In this episode of the “Cancer Horizons” podcast, a physician assistant recalls his experience as a frontline health care worker during the COVID-19 pandemic and what it was like to get diagnosed with multiple myeloma during such a chaotic time.
CURE spoke with Dr. Michael K. Wong and Dr. Diwakar Davar about the use of ctDNA for patients with melanoma, and where the field may be headed.
April 11th 2025

What Role May ctDNA Have in Melanoma Management?

Dr. Michael K. Wong
CURE spoke with Dr. Michael K. Wong and Dr. Diwakar Davar about the use of ctDNA for patients with melanoma, and where the field may be headed.
Bispecific antibodies target specific cells, offering effective treatment for relapsed/refractory multiple myeloma, with varying side effect profiles: © stock.adobe.com
April 4th 2025

Understanding the Use of Bispecific Antibodies in Multiple Myeloma

Ryan Scott
Bispecific antibodies target specific cells, offering effective treatment for relapsed/refractory multiple myeloma, with varying side effect profiles.